Seres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
August 2, 2018 7:00 AM EDT- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis -
- Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end -
- Recent Seres R&D event highlighted microbiome scientific leadership across several clinical and preclinical programs -
- Conference call at 8:30 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
